Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CBSCOTCMKTS:HBPCFNASDAQ:NRSNNASDAQ:OKUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBSCCardiac Biotech Solutions$0.05-9.8%$0.04$0.02▼$0.15$7.37M1.223,753 shs45,010 shsHBPCFHelix Biopharma$0.60$0.59$0.59▼$0.60$31.81M-0.151 shsN/ANRSNNeuroSense Therapeutics$1.90-4.0%$1.58$0.51▼$2.60$25.97M1.62280,831 shs566,342 shsOKUROnKure Therapeutics$2.40-4.8%$2.44$1.70▼$20.00$32.42M0.42109,465 shs93,296 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBSCCardiac Biotech Solutions0.00%-9.82%0.00%-9.82%-25.00%HBPCFHelix Biopharma0.00%0.00%0.00%+31.90%+335.73%NRSNNeuroSense Therapeutics0.00%-19.15%+26.67%+90.95%+123.11%OKUROnKure Therapeutics0.00%+1.27%-5.88%-46.19%+239,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBSCCardiac Biotech SolutionsN/AN/AN/AN/AN/AN/AN/AN/AHBPCFHelix BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ANRSNNeuroSense Therapeutics2.2849 of 5 stars3.53.00.00.02.21.70.0OKUROnKure Therapeutics3.1455 of 5 stars3.70.00.00.02.22.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBSCCardiac Biotech Solutions 0.00N/AN/AN/AHBPCFHelix Biopharma 0.00N/AN/AN/ANRSNNeuroSense Therapeutics 3.00Buy$14.00636.84% UpsideOKUROnKure Therapeutics 3.33Buy$32.331,247.22% UpsideCurrent Analyst Ratings BreakdownLatest CBSC, NRSN, OKUR, and HBPCF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025NRSNNeuroSense TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025NRSNNeuroSense TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.004/30/2025OKUROnKure TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBSCCardiac Biotech Solutions$140K52.61N/AN/AN/A∞HBPCFHelix BiopharmaN/AN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/A$0.19 per shareN/AOKUROnKure TherapeuticsN/AN/AN/AN/A$7.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBSCCardiac Biotech SolutionsN/AN/A0.00∞N/AN/AN/AN/AN/AHBPCFHelix Biopharma-$6.82M-$0.14N/A∞N/AN/AN/A-694.39%N/ANRSNNeuroSense Therapeutics-$10.21M-$0.54N/A∞N/AN/AN/A-445.40%N/AOKUROnKure Therapeutics-$52.67M-$5.26N/AN/AN/AN/A-49.13%-45.72%8/12/2025 (Estimated)Latest CBSC, NRSN, OKUR, and HBPCF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/16/2025Q3 2025HBPCFHelix BiopharmaN/A-$0.02N/A-$0.02N/AN/A5/6/2025Q1 2025OKUROnKure Therapeutics-$1.41-$1.19+$0.22-$1.19N/AN/A4/7/2025Q4 2024NRSNNeuroSense Therapeutics-$0.12-$0.06+$0.06-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBSCCardiac Biotech SolutionsN/AN/AN/AN/AN/AHBPCFHelix BiopharmaN/AN/AN/AN/AN/ANRSNNeuroSense TherapeuticsN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBSCCardiac Biotech SolutionsN/AN/AN/AHBPCFHelix BiopharmaN/A0.990.99NRSNNeuroSense TherapeuticsN/A2.212.21OKUROnKure TherapeuticsN/A11.1811.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBSCCardiac Biotech SolutionsN/AHBPCFHelix BiopharmaN/ANRSNNeuroSense Therapeutics1.04%OKUROnKure Therapeutics90.98%Insider OwnershipCompanyInsider OwnershipCBSCCardiac Biotech SolutionsN/AHBPCFHelix Biopharma7.60%NRSNNeuroSense Therapeutics27.40%OKUROnKure Therapeutics2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBSCCardiac Biotech Solutions5163.67 millionN/ANot OptionableHBPCFHelix Biopharma953.02 million48.99 millionNot OptionableNRSNNeuroSense Therapeutics1013.67 million9.92 millionNot OptionableOKUROnKure TherapeuticsN/A13.51 million13.20 millionN/ACBSC, NRSN, OKUR, and HBPCF HeadlinesRecent News About These CompaniesOnKure Therapeutics, Inc. (NASDAQ:OKUR) Receives $32.33 Consensus Target Price from BrokeragesJune 22, 2025 | americanbankingnews.comOKUR OnKure Therapeutics, Inc.June 12, 2025 | seekingalpha.comBuy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial PositionJune 3, 2025 | tipranks.comInsider Selling: OnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Sells 1,813,439 Shares of StockMay 20, 2025 | insidertrades.comOnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Cormorant Asset Management, Lp Sells 24,300 SharesMay 15, 2025 | insidertrades.comMajor Shareholder Sells Thousands of OnKure Therapeutics Shares!May 14, 2025 | tipranks.comPromising Developments and Positive Trial Results Reinforce Buy Rating for OnKure TherapeuticsMay 9, 2025 | tipranks.comOnKure increased R&D spending in 1Q with drug trials underwayMay 7, 2025 | bizwest.comBOnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | finanznachrichten.deOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | OKUR ...May 6, 2025 | gurufocus.comOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | gurufocus.comOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | globenewswire.comOnKure Therapeutics (OKUR) Receives Outperform Rating from Evercore ISI | OKUR Stock NewsApril 30, 2025 | gurufocus.comOnKure Therapeutics, Inc. Class A Common Stock (OKUR) ChartsApril 16, 2025 | nasdaq.comWhy OnKure Therapeutics, Inc.’s (OKUR) Stock Is Down 19.54%April 5, 2025 | aaii.comAOnKure Therapeutics price target lowered to $34 from $40 at H.C. WainwrightMarch 18, 2025 | markets.businessinsider.comPromising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025March 18, 2025 | tipranks.comWill OnKure Therapeutics (NASDAQ:OKUR) Spend Its Cash Wisely?March 12, 2025 | finance.yahoo.comOptimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future ProspectsMarch 12, 2025 | tipranks.comOnKure Therapeutics Reports Progress and FinancialsMarch 11, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCBSC, NRSN, OKUR, and HBPCF Company DescriptionsCardiac Biotech Solutions OTCMKTS:CBSC$0.05 0.00 (-9.82%) As of 06/27/2025 11:42 AM EasternCB Scientific, Inc., through its US and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.Helix Biopharma OTCMKTS:HBPCF$0.60 0.00 (0.00%) As of 06/27/2025Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.NeuroSense Therapeutics NASDAQ:NRSN$1.90 -0.08 (-4.04%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.88 -0.01 (-0.79%) As of 06/27/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.OnKure Therapeutics NASDAQ:OKUR$2.40 -0.12 (-4.76%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$2.40 0.00 (-0.21%) As of 06/27/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
